Miro Sciences Ltd (ASX:MSX)

Market Cap	20.66M -52.2%
Revenue (ttm)	402.66K
Net Income	-4.69M
EPS	-0.01
Shares Out	389.72M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	80,500
Open	0.0520
Previous Close	0.0540
Day's Range	0.0500 - 0.0530
52-Week Range	0.0410 - 0.1800
Beta	1.23
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Miro Sciences

Miro Sciences Ltd engages in the research and development of biomedical products targeting neurodegenerative conditions and immune-mediated inflammatory diseases. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. Miro Sciences Ltd was formerly known NeuroScientific Biopharmaceuticals Limited and change its name to Miro Sciences Ltd in October 2026. The company was incorporated in 2002 and is based in Ned...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MSX

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 29, 2026

Data Sources Report a data error